Healthcare Providers and Services
Company Overview of The Vanderbilt-Ingram Cancer Center
The Vanderbilt-Ingram Cancer Center engages in cancer research, treatment, support, prevention, education, and outreach. Its cancer clinics and programs include cancer information programs, cancer supportive care clinics, and patient resource centers, as well as medical, radiation, and surgical oncology centers; and bone and soft tissue, brain tumor, endocrine surgery, gastroenterology, general clinical research, hematology, otolaryngology, outpatient transplant, patient and family support, plastic surgery, thoracic surgery, and urology clinics and programs. The company also owns specific cancer units, including gastrointestinal, gynecologic, head and neck, orthopaedic, rehabilitation thorac...
691 Preston Building
Nashville, TN 37232
Founded in 1993
Key Executives for The Vanderbilt-Ingram Cancer Center
Compensation as of Fiscal Year 2015.
The Vanderbilt-Ingram Cancer Center Key Developments
Incyte Corporation and Vanderbilt-Ingram Cancer Center Establish Multi-Year Oncology Research Alliance
Jul 7 15
Incyte Corporation announced that it has entered into a multi-year research support and collaboration agreement with Vanderbilt-Ingram Cancer Center (VICC) at Vanderbilt University Medical Center (VUMC), whereby Incyte will provide funding for certain aspects of Vanderbilt’s cancer research activities. This alliance is designed to develop an improved understanding of basic cancer biology and the mechanisms of action of certain Incyte-proprietary compounds, as well as identify and develop novel approaches to patient selection which may enable new therapeutic opportunities in oncology.
Insight Genetics, Inc. and Vanderbilt-Ingram Cancer Center Partner to Improve Breast Cancer Diagnosis and Treatment
Mar 3 14
Insight Genetics, Inc. announced that it is collaborating with Vanderbilt-Ingram Cancer Center (VICC) to enhance how researchers and oncologists classify and treat patients diagnosed with triple-negative breast cancer (TNBC) and to identify genetic markers that will help select the targeted therapeutics most effective for each individual TNBC patient. The American Cancer Society estimates that more than 230,000 women will be diagnosed with an invasive form of breast cancer in 2014. Breast tumors that do not express genes for any of these three known markers are classified as triple-negative breast cancers. Patients with TNBC currently have limited treatment options and a higher risk of relapse than other forms of the disease. As part of their research project, Insight Genetics will be collaborating with Jennifer Pietenpol, Ph.D., director of VICC, and B.F. Byrd Jr., Professor of Oncology, as well as the laboratory group at VICC in a continuation of their work to identify novel genetic markers for TNBC. Recent work from the Pietenpol laboratory published in the Journal of Clinical Investigation used an algorithm to examine gene expression data from more than 500 TNBC cases and identified up to six distinct sub-types of triple-negative breast cancers. Insight Genetics and Dr. Pietenpol will now focus on identifying novel genetic drivers for these various TNBC sub-types and developing a better understanding of effective treatment options for each. The work is also designed to identify new TNBC biomarkers and develop assays based on these biomarkers.
Vanderbilt-Ingram Cancer Center and GenomOncology Announces an Agreement for the Exclusive Commercial Development of Decision Support Tool Based on My Cancer Genome
Feb 13 14
Vanderbilt-Ingram Cancer Center and GenomOncology have announced an agreement for the exclusive commercial development of a decision support tool based on My Cancer Genome, an online precision cancer medicine knowledge resource for physicians, patients, caregivers and researchers. The agreement should improve the way oncologists deliver genome-directed care across the country. Through this collaboration, GenomOncology, based in Westlake, Ohio, and VICC will enhance My Cancer Genome through the development of a new genomics content management tool. The MyCancerGenome.org website will remain free and open to the public. In addition, GenomOncology will develop a decision support tool based on My Cancer Genome data that will enable automated interpretation of mutations in the genome of a patient's tumor, providing actionable results in hours versus days. According to the terms of the agreement, all commercial use of My Cancer Genome in any form will be licensed through GenomOncology.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|